The role of carnitine in normal and altered fatty acid metabolism

American Journal of Kidney Diseases

Volumn 41, Issue 4 SUPPL. 4, 2003, Pages

  Hoppel, Charles ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Chronic renal failure (CRF); Congestive cardiomyopathy; Dialysis; End stage renal disease (ESRD); Fatty acid metabolism; Kidney failure; Levocarnitine (L carnitine); Lipid peroxidation; Uremia

Indexed keywords

ACYL COENZYME A; ACYLCARNITINE; ACYLTRANSFERASE; CARNITINE; FATTY ACID; LYSINE; METHIONINE;

BIOSYNTHESIS; CARNITINE DEFICIENCY; DIET; DRUG STRUCTURE; EXERCISE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HEART FUNCTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPID PEROXIDATION; LIPOLYSIS; MAMMAL; MEMBRANE PERMEABILITY; MITOCHONDRIAL RESPIRATION; MOLECULAR WEIGHT; MUSCLE CRAMP; MYOCARDIAL DISEASE; PEROXISOME; REVIEW; STRUCTURE ANALYSIS;

EID: 0037385059     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00112-4     Document Type: Review

References (75)

1. Gulewitsch W, Krimberg R: Zur Kenntnis der Extraktivstoffe der Muskeln. II. Mitteilung. Uber das Carnitin. Hoppe-Seyler's Z Physiol Chem 45:326-330, 1905
2. Tomita M, Sendju Y: Uber die Oxyaminoverbindungen, welche die Biuretreaktion ziegen. III. Spaltung der m-amino-b-oxybuttersaure in die optisch-aktiven Komponenten. Hoppe-Seyler's Z Physiol Chem 169:263-277, 1927
3. Kaneko T, Yoshida R: On the absolute configuration of L-carnitine (vitamin BT). Bull Chem Soc Jpn 35:1153-1155, 1962
4. Bremer J: Carnitine - Metabolism and functions. Physiol Rev 63:1420-1480, 1983
5. Fraenkel G, Friedman S: Carnitine, in Harris RS, Marrian GF, Thimann KV (eds): Vitamins and Hormones New York, NY, Academic, 1957, pp 73-118
6. Rebouche CJ, Paulson DJ: Carnitine metabolism and function in humans. Annu Rev Nutr 6:41-66, 1986
7. Rebouche CJ, Seim H: Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 18:39-61, 1998
8. Kerner J, Hoppel C: Genetic disorders of carnitine metabolism and their nutritional management. Annu Rev Nutr 18:179-206, 1998
9. Rebouche CJ, Engel AG: Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. J Clin Invest 73:857-867, 1984
10. LaBadie J, Dunn WA, Aronson NN Jr: Hepatic synthesis of carnitine from protein-bound trimethyl-lysine. Lysosomal digestion of methyl-lysine-labelled asialo-fetuin. Biochem J 160:85-95, 1976
11. Davis AT, Hoppel CL: Effect of starvation on the disposition of free and peptide-linked trimethyllysine in the rat. J Nutr 116:760-767, 1986
12. Borum PR: Carnitine. Annu Rev Nutr 3:233-259, 1983
13. Hoppel CL, Davis AT: Inter-tissue relationships in the synthesis and distribution of carnitine. Biochem Soc Trans 14:673-674, 1986
14. Hokland BM, Bremer J: Metabolism and excretion of carnitine and acylcarnitines in the perfused rat kidney. Biochim Biophys Acta 886:223-230, 1986
15. Clouet P, Niot I, Bezard J: Pathway of alpha-linolenic acid through the mitochondrial outer membrane in the rat liver and influence on the rate of oxidation. Comparison with linoleic and oleic acids. Biochem J 1263:867-873, 1989
16. Kerner J, Hoppel C: Fatty acid import into mitochondria. Biochim Biophys Acta 1486:1-17, 2000
17. Parvin R, Pande SV: Enhancement of mitochondrial carnitine and carnitine acylcarnitine translocase-mediated transport of fatty acids into liver mitochondria under ketogenic conditions. J Biol Chem 254:5423-5429, 1979
18. Bieber LL: Carnitine. Annu Rev Biochem 57:261-283, 1988
19. Ramsay RR, Gandour RD: Selective modulation of carnitine long-chain acyltransferase activities. Kinetics, inhibitors, and active sites of COT and CPT-II. Adv Exp Med Biol 466:103-109, 1999
20. Brady PS, Ramsay RR, Brady LJ: Regulation of the long-chain carnitine acyltransferases. FASEB J 7:1039-1044, 1993
21. Brass EP, Hoppel CL: Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem J 190:495-504, 1980
22. Brass EP, Hoppel CL: Effect of carnitine on mitochondrial oxidation of palmitoylearnitine. Biochem J 188:451-458, 1980
23. Lysiak W, Toth PP, Suelter CH, Bieber LL: Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J Biol Chem 261:13698-13703, 1986
24. Lysiak W, Lilly K, DiLisa F, Toth PP, Bieber LL: Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem 263:1151-1156, 1988
25. Hiatt WR, Regensteiner JG, Wolfel EE, Ruff L, Brass EP: Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state. J Clin Invest 84:1167-1173, 1989
26. Hokland BM: Uptake, metabolism and release of carnitine and acylcarnitines in the perfused rat liver. Biochim Biophys Acta 961:234-241, 1988
27. Kerner J, Bieber LL: Isolation and identification of alpha-methyloctanylcarnitines from human urine. Prep Biochem 15:237-257, 1985
28. Brass EP, Beyerinck RA: Effects of propionate and carnitine on the hepatic oxidation of short- and mediumchain-length fatty acids. Biochem J 250:819-825, 1988
29. Leighton F, Bergseth S, Rortveit T, Christiansen EN, Bremer J: Free acetate production by rat hepatocytes during peroxisomal fatty acid and dicarboxylic acid oxidation. J Biol Chem 264:10347-10350, 1989
30. Buechler KF, Lowenstein JM: The involvement of carnitine intermediates in peroxisomal fatty acid oxidation: A study with 2-bromofatty acids. Arch Biochem Biophys 281:233-238, 1990
31. Wanders RJ, Denis S, Ruiter JP, Schutgens RB, van Roermund CW, Jacobs BS: Measurement of peroxisomal fatty acid beta-oxidation in cultured human skin fibroblasts. J Inherit Metab Dis 18:113-124, 1995
32. Ramsay RR: The role of the carnitine system in peroxisomal fatty acid oxidation. Am J Med Sci 318:28-35, 1999
33. van Hinsbergh VW, Veerkamp JH, Cordewener JH: Effect of carnitine and branched-chain acylcarnitines on the 2-oxo acid dehydrogenase activity in intact mitochondria of rat muscle. Int J Biochem 12:559-565, 1980
34. Hokland BM, Bremer J: Formation and excretion of branched-chain acylcamitines and branched-chain hydroxy acids in the perfused rat kidney. Biochim Biophys Acta 961:30-37, 1988
35. Branca D, Di Lisa F, Scutari G, Toninello A, Siliprandi N: Stabilizing action of L-carnitine on the energy-linked processes of mitochondria isolated from perfused rat liver. Biochem Pharmacol 35:2839-2841, 1986
36. Branca D, Toninello A, Scutari G, et al: Involvement of long-chain acyl CoA in the antagonistic effects of halothane and L-carnitine on mitochondrial energy-linked processes. Biochem Biophys Res Commun 139:303-307, 1986
37. Carter AL, Abney TO, Lapp DF: Biosynthesis and metabolism of carnitine. J Child Neurol 10:S3-S7, 1995 (suppl 2)
38. Bremer J: The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 28:297-301, 1990
39. Pons R, De Vivo DC: Primary and secondary carnitine deficiency syndromes. J Child Neurol 10:S8-24, 1995 (suppl 2)
40. Rebouche CJ, Engel AG: Carnitine metabolism and deficiency syndromes. Mayo Clin Proc 58:533-540, 1983
41. Famularo G, Matricardi F, Nucera E, Santini G, De Simone C: Carnitine deficiency: Primary and secondary syndromes, in De Simone C, Famularo G (eds): Carnitine Today. Austin, TX, Landes Bioscience, 1997, pp 119-161
42. DiDonato S, Gellera C, Peluchetti D, et al: Normalization of short-chain acylcoenzyme A dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme A dehydrogenase-deficient myopathy. Ann Neurol 25:479-484, 1989
43. Hale DE, Batshaw ML, Coates PM, et al: Long-chain acyl coenzyme A dehydrogenase deficiency: An inherited cause of nonketotic hypoglycemia. Pediatr Res 19:666-671, 1985
44. Regitz V, Shug AL, Fleck E: Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65:755-760, 1990
45. Rizos I: Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 139:S120-S123, 2000 (suppl 2, part 3)
46. Vary TC, Neely JR: A mechanism for reduced myocardial carnitine levels in diabetic animals. Am J Physiol 243:H154-H158, 1982
47. Regitz-Zagrosek V, Fleck E: Myocardial carnitine deficiency in human cardiomyopathy, in de Jong JW, Ferrari R (eds): The Carnitine System Dordercht, The Netherlands, Kluwer, 1995, pp 145-166
48. Saris NE, Eriksson KO: Mitochondrial dysfunction in ischaemia-reperfusion. Acta Anaesthesiol Scand Suppl 107: S171-S176, 1995
49. Fujisawa S, Kobayashi A, Hironaka Y, Yamazaki N: Effect of L-carnitine on the cellular distribution of carnitine and its acyl derivatives in the ischemic heart. Jpn Heart J 33:693-705, 1992
50. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E: Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 131:146-152, 1996
51. Corr PB, Yamada KA: Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis. Herz 20:156-168, 1995
52. Kashiwagi A, Kanno T, Arita K, Ishisaka R, Utsumi T, Utsumi K: Suppression of T(3)- and fatty acid-induced membrane permeability transition by L-carnitine. Comp Biochem Physiol B Biochem Mol Biol 130:411-418, 2001
53. Furuno T, Kanno T, Arita K, et al: Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 62:1037-1046, 2001
54. McCallum CD, Epand RM: Insulin receptor autophosphorylation and signaling is altered by modulation of membrane physical properties. Biochemistry 34:1815-1824, 1995
55. Serdar A, Yesilbursa D, Serdar Z, Dirican M, Turel B, Cordan J: Relation of functional capacity with the oxidative stress and antioxidants in chronic heart failure. Congest Heart Fail 7:309-311, 2001
56. Polidori MC, Savino K, Alunni G, et al: Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: Relationship to disease severity. Free Radic Biol Med 32:148-152, 2002
57. Ma A, Zhang W, Liu Z: Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 3:S53-S55, 1996
58. Ahmad S: L-Carnitine in dialysis patients. Semin Dial 14:209-217, 2001
59. Ricanati ES, Tserng KY, Hoppel CL: Abnormal fatty acid utilization during prolonged fasting in chronic uremia. Kidney Int Suppl 22:S145-S148, 1987
60. Maeda K, Shinzato T, Kobayakawa H: Effects of L-carnitine administration on short-chain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 51:355-361, 1989
61. Suzuki Y, Narita M, Yamazaki N: Effects of L-carnitine on arrhythmias during hemodialysis. Jpn Heart J 23:349-359, 1982
62. Savica V, Bellinghieri G, Di Stefano C, et al: Plasma and muscle carnitine levels in haemodialysis patients with morphological-ultrastructural examination of muscle samples. Nephron 35:232-236, 1983
63. Sakurabayashi T, Takaesu Y, Haginoshita S, et al: Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Am J Nephrol 19:480-484, 1999
64. Usberti M, Gerardi GM, Gazzotti RM, et al: Oxidative stress and cardiovascular disease in dialyzed patients. Nephron 91:25-33, 2002
65. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001
66. Smogorzewski M, Perna AF, Borum PR, Massry SG: Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and CRF. Kidney Int 34:797-803, 1988
67. Sommerburg O, Grune T, Hampl H, Riedel E, Ehrich JH, Siems WG: Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients? Clin Nephrol 53:S23-S29, 2000 (suppl 1)
68. Gallucci MT, Lubrano R, Meloni C, et al: Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol 52: 239-245, 1999
69. Hiatt WR, Koziol BJ, Shapiro JI, Brass EP: Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 41:1613-1619, 1992
70. Kudoh Y, Shoji T, Oimatsu H, Yoshida S, Kikuchi K, Iimura O: The role of L-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis. Jpn Circ J 47:1391-1397, 1983
71. Matsumoto Y, Amano I, Hirose S, et al: Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif 19:24-32, 2001
72. Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H: Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 72:574-578, 1996
73. Pepine CJ: The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 13:2-21, 1991
74. Brass EP: Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 17:176-185, 1995
75. Goa KL, Brogden RN: L-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 34:1-24, 1987